ES2114887T3 - UTILIZATION OF NEXIN-I PROTEASE INDUCING WOUND HEALING. - Google Patents

UTILIZATION OF NEXIN-I PROTEASE INDUCING WOUND HEALING.

Info

Publication number
ES2114887T3
ES2114887T3 ES91907406T ES91907406T ES2114887T3 ES 2114887 T3 ES2114887 T3 ES 2114887T3 ES 91907406 T ES91907406 T ES 91907406T ES 91907406 T ES91907406 T ES 91907406T ES 2114887 T3 ES2114887 T3 ES 2114887T3
Authority
ES
Spain
Prior art keywords
wound healing
nexin
utilization
inducing wound
protease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91907406T
Other languages
Spanish (es)
Inventor
Randy W Scott
Richard A Berg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Incyte Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Pharmaceuticals Inc filed Critical Incyte Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2114887T3 publication Critical patent/ES2114887T3/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
    • A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
    • A61L2300/104—Silver, e.g. silver sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A61L2300/254—Enzymes, proenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A61L2300/406—Antibiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A61L2300/414—Growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/42—Anti-thrombotic agents, anticoagulants, anti-platelet agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Materials Engineering (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

SE PRESENTA UN METODO PARA PROMOVER LA CURACION DE HERIDAS CON UNA COMPOSICION QUE CONTIENE PROTEASA NEXIN-I (PN-I). SE PRESENTAN COMPOSICIONES QUE COMPRENDEN PN-I UNIFORMEMENTE DISPERSO A TRAVES DE UN PORTADOR FARMACOLOGICAMENTE ACEPTABLE.A METHOD FOR PROMOTING WOUND HEALING WITH A COMPOSITION CONTAINING PROTEASE NEXIN-I (PN-I) IS PRESENTED. COMPOSITIONS INCLUDING PN-I ARE PRESENTED UNIFORMLY DISPERSED THROUGH A PHARMACOLOGICALLY ACCEPTABLE CARRIER.

ES91907406T 1990-04-05 1991-04-01 UTILIZATION OF NEXIN-I PROTEASE INDUCING WOUND HEALING. Expired - Lifetime ES2114887T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/505,442 US5112608A (en) 1987-03-13 1990-04-05 Use of protease nexin-I to mediate wound healing

Publications (1)

Publication Number Publication Date
ES2114887T3 true ES2114887T3 (en) 1998-06-16

Family

ID=24010332

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91907406T Expired - Lifetime ES2114887T3 (en) 1990-04-05 1991-04-01 UTILIZATION OF NEXIN-I PROTEASE INDUCING WOUND HEALING.

Country Status (9)

Country Link
US (1) US5112608A (en)
EP (1) EP0556178B1 (en)
JP (1) JP3150338B2 (en)
AT (1) ATE163861T1 (en)
AU (1) AU647120B2 (en)
CA (1) CA2079783A1 (en)
DE (1) DE69129071T2 (en)
ES (1) ES2114887T3 (en)
WO (1) WO1991015233A1 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8602626D0 (en) * 1986-02-04 1986-03-12 Ciba Geigy Ag Neurite-promoting factor
US5196196A (en) * 1986-06-03 1993-03-23 Incyte Pharmaceuticals, Inc. Use of protease nexin-I in wound dressings
US5206017A (en) * 1986-06-03 1993-04-27 Incyte Pharmaceuticals, Inc. Use of protease nexin-I as an antiinflammatory
US5278049A (en) * 1986-06-03 1994-01-11 Incyte Pharmaceuticals, Inc. Recombinant molecule encoding human protease nexin
US5326562A (en) * 1986-06-03 1994-07-05 Incyte Pharmaceuticals, Inc. Pharmaceutical dosage unit for treating inflammation comprising protease nexin-I
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5756094A (en) * 1991-03-27 1998-05-26 Trustees Of The University Of Pennsylvania Methods for stimulating follicular growth
US5705178A (en) * 1991-05-31 1998-01-06 Gliatech, Inc. Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers
US5605938A (en) * 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
IL107578A (en) * 1993-11-11 1998-07-15 Yissum Res Dev Co Topical antibacterial preparation comprising silver sulfadiazine and collagen
EP0821592A4 (en) * 1995-04-20 2000-03-01 Univ Pennsylvania COMPOSITIONS AND METHODS FOR REGULATING HAIR GROWTH
US5641483A (en) * 1995-06-07 1997-06-24 Beaulieu; Andre Wound healing formulations containing human plasma fibronectin
US7112320B1 (en) 1995-06-07 2006-09-26 Andre Beaulieu Solid wound healing formulations containing fibronectin
US5877149A (en) 1995-06-07 1999-03-02 Beaulieu; Andre Deepithelialized skin diffusion cell system
US5733884A (en) 1995-11-07 1998-03-31 Nestec Ltd. Enteral formulation designed for optimized wound healing
SE9600216D0 (en) * 1996-01-18 1996-01-18 Hans Arne Hansson Control of healing processes
US20050208114A1 (en) * 1998-03-24 2005-09-22 Petito George D Composition and method for healing tissues
US6673623B1 (en) 2000-09-12 2004-01-06 Novocure, Inc. Methods and compositions that control lipid production
US6600057B2 (en) 2000-12-29 2003-07-29 Kimberly-Clark Worldwide, Inc. Matrix metalloproteinase inhibitors
US7041787B2 (en) * 2000-12-29 2006-05-09 Kimberly-Clark Worldwide, Inc. Design and use of advanced zinc chelating peptides to regulate matrix metalloproteinases
US20030119073A1 (en) * 2001-12-21 2003-06-26 Stephen Quirk Sensors and methods of detection for proteinase enzymes
CA2537246A1 (en) * 2003-09-03 2005-03-17 Kringle Pharma Inc. Skin ulcer preventive or curative agent containing human recombinant hgf
EP2226382A1 (en) 2009-03-03 2010-09-08 B.R.A.I.N. Biotechnology Research and Information Network AG Protease for wound conditioning and skin care

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4265233A (en) * 1978-04-12 1981-05-05 Unitika Ltd. Material for wound healing
EP0233838A3 (en) * 1986-02-04 1990-01-31 Incyte Pharmaceuticals, Inc. Neurite-promoting factor and process for the manufacture thereof
DE3606265A1 (en) * 1986-02-27 1987-09-03 Roehm Pharma Gmbh POLYSACCHARID-BASED Wound Dressing As a Carrier Therapeutically Effective, Non-Immobilized Enzymes and with High Absorbency
US5006252A (en) * 1986-06-03 1991-04-09 Invitron Purified protease nexin
AU6879091A (en) * 1989-10-16 1991-05-16 Invitron Corporation Protease nexin i/dextran sulfate anticoagulant

Also Published As

Publication number Publication date
US5112608A (en) 1992-05-12
ATE163861T1 (en) 1998-03-15
AU7680391A (en) 1991-10-30
JPH05508148A (en) 1993-11-18
EP0556178A1 (en) 1993-08-25
CA2079783A1 (en) 1991-10-06
AU647120B2 (en) 1994-03-17
DE69129071T2 (en) 1998-10-29
DE69129071D1 (en) 1998-04-16
WO1991015233A1 (en) 1991-10-17
EP0556178B1 (en) 1998-03-11
EP0556178A4 (en) 1993-04-27
JP3150338B2 (en) 2001-03-26

Similar Documents

Publication Publication Date Title
ES2106965T3 (en) NEW 4-AZA-5ALFA-ANDROSTAN-3-ONAS 7BETA-REPLACED AS INHIBITORS OF 5ALFA-REDUCTASA.
ES2040261T3 (en) PROCEDURE FOR PREPARING 6-FLUOR-4-OXO-1,4-DIHYDROKINOLINE-3-CARBOXYLIC ACIDS AND 9-FLUOR-3-METHYL-7-OXO-2,3-DIHYDRO-7H-PIRIDO (1,2, 3-DE) (1,4) BENZOXAZINA-6-CARBOXILICO SUBSTITUTED.
ES2059446T3 (en) COMPOSITION OF A SPECIFIC HYDROGENATED BLOCK COPOLYMER AND PROCESS FOR ITS MANUFACTURE.
FI873363A0 (en) FOERFARANDE FOER FRAMSTAELLNING AV LAEKEMEDEL MED ANTITUMOERAKTIVITET.
ES522310A0 (en) A METHOD OF TREATING A SUBSTANTIALLY DRY COMPOSITION INCLUDING BLOOD PLASMA FACTOR VIII.
ES553821A0 (en) A PROCEDURE FOR THE PREPARATION OF NEW SUBSTITUTED AZETIDINONES.
ES2144192T3 (en) NEW DERIVATIVES OF 1-PHENYL-2-DIMETHYL-AMINO-METHYL-CICLOHEXAN-1-OL, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
BR9101065A (en) COMPACT FLUORESCENT LAMP
BR9306683A (en) Aldehyde-cured proteinaceous adhesive
ES2039226T3 (en) PROCEDURE FOR PREPARING COMPOSITIONS CONTAINING POLYCARBOFIL.
GR900100380A (en) Method of preparation of anti-inflammatory derivatives of aminophenol.
FI843409A0 (en) Fluorometer.
ATE26115T1 (en) SUBSTITUTED 8-PHENYLXANTHINS.
DE69530403D1 (en) KERATINOCYTE GROWTH FACTOR ANALOGS
ES2044087T3 (en) A METHOD FOR PREPARING A COMPOSITION OF STABILIZED 13,14-DIHYDRO-15-CETOPROSTAGLANDINE.
BG37995A3 (en) Method for preparing derivatives of 2- cyanbenzimidazol
NO944406L (en) New 7 e inhibitors
ES2067822T3 (en) ISOPRENOID PHOSPHOLIPASE A2 INHIBITORS AND PREPARATIONS CONTAINING THEM.
BG35328A3 (en) Method for preparing imidodisulphamidic derivatives
ES2095068T3 (en) POLYMERIC PEROXYCARBONATES AND PROCEDURE FOR PREPARING THEM.
ES2177811T3 (en) USE OF NITROFLAVONOIDS FOR THE TREATMENT OF ANXIETY.
BR8905745A (en) FRAGRANCE COMPOSITION, PROCESS FOR THE PREPARATION OF COMPOUNDS AND USE OF THESE COMPOUNDS
DK448587A (en) STEREOISOMS FORM OF CERTAIN PHENYLETHANOLAMNIDE DERIVATIVES
FI853768A0 (en) SYNERGISTIC SAMMING SET FOR FOUNDATION.
ES2071025T3 (en) SOFTENING COMPOSITION OF FABRICS.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 556178

Country of ref document: ES